Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

KRON

Kronos Bio (KRON)

Kronos Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KRON
DateTimeSourceHeadlineSymbolCompany
2:30PMiHub NewswireFeaturedIntegrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share
05/09/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
05/09/20244:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
05/09/20244:05PMGlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
04/24/20244:01PMGlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
03/21/20247:05AMGlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
03/07/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
03/07/20244:05PMGlobeNewswire Inc.Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayNASDAQ:KRONKronos Bio Inc
03/05/20244:44PMGlobeNewswire Inc.Kronos Bio To Present Three Posters at AACR 2024 Annual MeetingNASDAQ:KRONKronos Bio Inc
03/05/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
02/27/20244:05PMGlobeNewswire Inc.Kronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceNASDAQ:KRONKronos Bio Inc
02/23/20248:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
02/23/20248:06PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
02/23/20248:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
02/23/20248:03PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
01/25/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
01/05/20246:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
01/05/20246:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
01/05/20246:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
12/18/20234:06PMGlobeNewswire Inc.Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateNASDAQ:KRONKronos Bio Inc
12/13/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
12/13/20234:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
12/04/20238:00AMGlobeNewswire Inc.Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:KRONKronos Bio Inc
11/27/20234:05PMGlobeNewswire Inc.Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:KRONKronos Bio Inc
11/13/20234:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
11/13/20234:05PMGlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
11/13/20234:04PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
11/02/20234:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
11/02/20234:05PMGlobeNewswire Inc.Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 StudyNASDAQ:KRONKronos Bio Inc
11/02/202312:00PMGlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
 Showing the most relevant articles for your search:NASDAQ:KRON

Your Recent History